CTLA4 and Miyoshi myopathy: However, those ICBs do not exert a satisfactorily inhibitory impact on MM as they do on CM, showing the ORR to anti-CTLA4 or anti-PD1/PDL1 as the single agent from 7% to 35% (136, 172–174).